![Egetis Therapeutics, Audiocast with teleconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ccae4327-1104-4f97-af74-b63e21b9bd83.png)
Egetis Therapeutics
4,635 SEK -2,01%Vær den første som følger denne virksomhed
Egetis Therapeutics is a drug development company, focused on projects in late clinical development in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs. Examples of the company's drug candidates are Emcitate, which is developed for patients with MCT8 deficiency, and Aladote, which is developed to reduce acute liver damage.
Omsætning
57,6 mio.
EBIT %
-563,89 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
EGTX
Daglig lav / høj pris
4,61 / 4,88
SEK
Markedsværdi
1,36 mia. SEK
Aktieomsætning
1,46 mio. SEK
Volumen
309 t
Seneste videoer
Finanskalender
Delårsrapport
22.08.2024
Delårsrapport
08.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Frazier Life Sciences | 13,2 % | 13,2 % |
Peder Walberg | 11,5 % | 11,5 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
![Egetis Therapeutics, Audiocast with teleconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ccae4327-1104-4f97-af74-b63e21b9bd83.png)
Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency
Egetis awarded Promising Innovative Medicine designation in the UK for Emcitate® (tiratricol) for treatment of MCT8 deficiency
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools